Composition and method for treating non-bacterial cystitis
OwnerFloyd A. Katske, Daniel Shoskesinventors
Life of this patent
Estimating the term…
Abstract
A composition and a method for treatment of urinary tract dysfunction and, particularly, non-bacterial cystitis and, even more particularly, non-bacterial chronic interstitial cystitis. The composition primarily relies upon the use of a bioflavonoid and, particularly, that bioflavonoid known as quercetin. The quercetin is mixed with a proteolytic digestive enzyme protease, such as bromelin and papain, as the primary active ingredients. However, the composition may optionally and beneficially include other cystitis affecting agents, such as cranberry, as well as some other active and non-active ingredients.
Claims22
A composition for the symptomatic treatment of non-bacterial interstitial cystitis said composition comprising:
- a) a bioflavonoid comprised of a substantial percentage of quercetin in an amount larger than the amounts of any other ingredients in the composition and exhibits anti-oxidant and anti-inflammatory qualities;
- and
- b) a digestive enzyme in an amount effective to increase the transmural intestinal absorption and bioavailability of the bioflavonoid, and to facilitate substantial transmural intestinal absorption of the bioflavonoid in a human body wherein absorption of the bioflavonoid is substantially greater than the amount of transmural intestinal absorption and bioavailability which would occur without the enzyme, wherein the enzyme and bioflavonoid composition reduces symptomatic effects of non-bacterial interstitial cystitis with is improved efficacy than the bioflavonoid alone.
A composition for the symptomatic treatment of non-bacterial interstitial cystitis, said composition comprising:
- a) a bioflavonoid comprised of a substantial percentage of quercetin and exhibits anti-oxidant and anti-inflammatory qualities and is present in an amount greater than the amounts of any other ingredients in the composition;
- b) a digestive enzyme comprising bromelain and papain in amounts effective to increase the transmural intestinal absorption and bioavailability of the bioflavonoid so that there is a transmural intestinal absorption of the bioflavonoid in a human body in an amount greater than that which would occur without the enzyme and in an amount to reduce symptomatic effects of non-bacterial interstitial cystitis, wherein the enzyme symptomatic effects of non-bacterial interstitial cystitis with improved efficacy than the bioflavonoid alone the presence of the digestive enzymes.
Dependencies are inferred from the claim text.